OPEC study: An international multicenter study of ovarian preservation in endometrial cancers

AKGÖR U., AYHAN A., Shushkevich A., Ozdal B., Angelou K., Akbayir O., ...More

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, vol.159, no.2, pp.550-556, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 159 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.1002/ijgo.14190
  • Journal Name: INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, MEDLINE, Public Affairs Index
  • Page Numbers: pp.550-556
  • Keywords: early-stage, endometrial cancer, ovarian preservation, young women, YOUNG-WOMEN, PREMENOPAUSAL WOMEN, CONSERVATION, SURVIVAL, ADENOCARCINOMA, GUIDELINES, OUTCOMES, SAFETY, IMPACT, RISK
  • Hacettepe University Affiliated: Yes

Abstract

Objective To evaluate the feasibility and oncological safety of ovarian preservation in early stage endometrial adenocarcinoma (EC) patients aged 40 and below. Methods A total of 11 institutions from eight countries participated in the study. 169 of 5898 patients aged <= 40 years were eligible for the study. Patients with EC treated between March 2007 and January 2019 were retrospectively assessed. Results The median duration of follow-up after EC diagnosis was 59 months (4-187). Among 169 participants, ovarian preservation surgery (OPS) was performed in 54 (31.9%), and BSO was performed in 115 (68.1%) patients. Although patients younger than 30 years of age were more likely to have OPS than patients aged 30 to 40 years (20.4% vs. 9.6%, P = 0.021), there was no significant difference by the mean age. There were no other relevant baseline differences between OPS and BSO groups. The Kaplan-Meier analysis revealed no difference in either the overall survival (P = 0.955) or recurrence-free survival (P = 0.068) among patients who underwent OPS, and BSO. Conclusion OPS appears to be safe without having any adverse impact on survival in women aged <= 40 years with FIGO Stage I EC.